Rapport therapeutics, inc. common stock RAPP.US Overview
RAPP AI Analysis & Strategy
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
RAPP Current Performance
4.82%
Rapport therapeutics, inc. common stock
2.83%
Avg of Sector
-0.07%
S&P500
RAPP Key Information
RAPP Financial Forecast
Unit : USD
RAPP Earnings Table
RAPP Profile
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
Price of RAPP
RAPP FAQ
When is RAPP's latest earnings report released?
The most recent financial report for Rapport therapeutics, inc. common stock (RAPP) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating RAPP’s short-term business performance and financial health. For the latest updates on RAPP’s earnings releases, visit this page regularly.
How much debt does RAPP have?
As of the end of the reporting period, Rapport therapeutics, inc. common stock (RAPP) had total debt of 7.84M, with a debt ratio of 0.03. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company’s capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does RAPP have?
At the end of the period, Rapport therapeutics, inc. common stock (RAPP) held Total Cash and Cash Equivalents of 57.71M, accounting for 0.19 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is RAPP's EPS continuing to grow?
According to the past four quarterly reports, Rapport therapeutics, inc. common stock (RAPP)’s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.68. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of RAPP?
Rapport therapeutics, inc. common stock (RAPP)’s Free Cash Flow (FCF) for the period is -20.53M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 9.85% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of RAPP?
The latest valuation data shows Rapport therapeutics, inc. common stock (RAPP) has a Price-To-Earnings (PE) ratio of -4.88 and a Price/Earnings-To-Growth (PEG) ratio of -0.06. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.